



THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX DAC

Applicants: Christine L. Brakel, *et al.*)
Serial No.: 08/479,999)
Filed: June 28, 1994)
Title: "Modified Nucleotide)
Compounds")

Group Art Unit: 1655

Examiner: Ardin H. Marschel, Ph.D.

Enzo Therapeutics, Inc.
c/o Enzo Biochem, Inc.
527 Madison Avenue, 9th Floor
New York, New York 10022

March 10, 2000

FILED BY EXPRESS MAIL

Assistant Commissioner for Patents
Box DAC
Washington, D.C. 20231

RECEIVED

MAR 14 2000

**RENEWED PETITION UNDER
37 C.F.R. § 1.137(b)**

OFFICE OF PETITIONS
DEPUTY A/C PATENTS

Sir:

Applicants submitted on November 19, 1999 a Petition To Revive An Unintentionally Abandoned Application Under 37 C.F.R. § 1.137(b). This petition was dismissed and a notice of the dismissal was mailed to Applicants on January 11, 2000.

The reasons for dismissing the petition was that (a) the petition does not contain a statement that the entire delay was unintentional as required, and (b) the petition lacked a terminal disclaimer (and fee as set forth in 37 CFR 1.20(d)) required by 37 CFR 1.137(c).

Applicants, by their undersigned attorney state, that the entire delay in filing the required reply from the April 4, 1999 due date until the filing of the Petition on November 19, 1999 and thence until the filing of this Renewed Petition was unintentional.

03/14/2000 SLUARDZ 0000003 051135 08473592
01 FC:240 55.00 CH

EXPRESS MAIL

"Express Mail" mailing label number: EL301951898US


Deposit Date: March 10, 2000

ENZ-47(C2)

Applicants: Christine L. Brakel
Serial No.: 08/479,999
Filed: June 28, 1994
Page 2 (Renewed Petition Under 37 CFR §1.137(b))

Applicants are herewith filing the requisite terminal disclaimer signed by an attorney of record. Applicants also hereby authorize the Patent and Trademark Office to charge Deposit Account No. 05-1135 for the requisite fee of \$55.00 set forth in 37 CFR 1.137(c); (and any other fees required in connection with the filing of this Renewed Petition). Applicants' status as a small entity has been previously established and still is applicable.

Accordingly, Applicants respectfully request that this application be revived as the entire delay in filing the required reply from the April 4, 1999 due date for the reply until the filing of this renewed Petition and terminal disclaimer was unintentional.


Ronald C. Fedus
Registration No. 32,567
John J. Santalone
Registration No. 32,794
Gary R. Molnar
Registration No. 30,299
Attorneys for Applicants

Enzo Diagnostics, Inc.
c/o Enzo Biochem, Inc.
527 Madison Avenue, 9th Floor
New York, New York 10022
Telephone: (212) 583-0100
Facsimile: (212) 583-0150